Macquarie Group
PLX icon

Macquarie Group’s Protalix BioTherapeutics PLX Stock Holding History

Macquarie Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,460
Closed -$4.05K – 1853
2024
Q2 		$4.05K Buy
+3,460
New +$4.09K ﹤0.01% 1740
2019
Q1 		– Sell
-2,910
Closed -$9K – 1944
2018
Q4 		$9K Sell
2,910
-7,064
-71% -$33.6K ﹤0.01% 1945
2018
Q3 		$73K Sell
9,974
-6,028
-38% -$30.3K ﹤0.01% 1656
2018
Q2 		$69K Buy
16,002
+11,872
+287% +$52.8K ﹤0.01% 1908
2018
Q1 		$22K Sell
4,130
-7,250
-64% -$47.7K ﹤0.01% 2073
2017
Q4 		$75K Buy
+11,380
New +$76.8K ﹤0.01% 1945

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Macquarie Group's PLX Position: Q3 2024 in Review

Macquarie Group sold out of Protalix BioTherapeutics (PLX) in Q3 2024, closing a stake of 3,460 shares — an estimated $4.05K sold.

Macquarie Group first reported a position in PLX in Q4 2017 and held it in 6 quarters. The position peaked at $75K in Q4 2017. 45 funds tracked by Wall St. Rank hold PLX as of Q3 2024.

  • Macquarie Group reported no remaining Protalix BioTherapeutics position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 3,460 Protalix BioTherapeutics shares in Q3 2024, an estimated $4.05K.
  • Macquarie Group first reported a position in Protalix BioTherapeutics in Q4 2017 and held it in 6 quarters.
  • Macquarie Group's Protalix BioTherapeutics position peaked at $75K in Q4 2017.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.